Martine Elias is the CEO of Myeloma Canada and has been in this role since 2016. Previously, they served in various director positions at The Janssen Pharmaceutical Companies of Johnson & Johnson from 2002 to 2015, where they developed and executed patient engagement strategies and managed government relations. Martine also held senior roles in market access at Sanofi-Synthelabo and GlaxoSmithKline, achieving notable improvements in reimbursement processes. They are currently a board member of the International Myeloma Foundation and are pursuing a Bachelor of Science in Biology at Université de Montréal.
This person is not in any offices